Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
暂无分享,去创建一个
C. Copie-Bergman | T. Molina | F. Jardin | G. Salles | B. Coiffier | J. Jais | T. Petrella | S. Mareschal | H. Tilly | T. Fest | F. Desmots | K. Leroy | C. Haioun | M. André | F. Peyrade | R. Delarue | P. Ruminy | J. Brière | M. Figeac | B. Fabiani | T. Lamy | D. Canioni | A. Bosly | É. Bohers | C. Maingonnat | N. Ketterer | P. Peyrouze | P. Bertrand | S. Dubois | P. Viailly
[1] C. Copie-Bergman,et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma , 2016, Genes, chromosomes & cancer.
[2] C. Copie-Bergman,et al. Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study , 2015 .
[3] L. Staudt,et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[5] M. Looney. Selectin' for NETs. , 2015, Blood.
[6] F. Jardin,et al. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis , 2015, Haematologica.
[7] T. Molina,et al. Accurate Classification of Germinal Center B-Cell-Like/Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase-Multiplex Ligation-Dependent Probe Amplification Assay: A CALYM Study. , 2015, The Journal of molecular diagnostics : JMD.
[8] F. Jardin,et al. Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era , 2015, Leukemia & lymphoma.
[9] O. Elemento,et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.
[10] A. Rosenwald,et al. The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum , 2015, Leukemia.
[11] F. Jardin,et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy? , 2015, Oncotarget.
[12] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[13] A. Salar,et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma , 2014, Leukemia.
[14] Jun Zhu,et al. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment , 2014, Cancer Cell International.
[15] F. Jardin,et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B‐cell lymphoma , 2014, Genes, chromosomes & cancer.
[16] C. Mullighan. Genome sequencing of lymphoid malignancies. , 2013, Blood.
[17] W. Choi,et al. Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study , 2013 .
[18] Steven J. M. Jones,et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.
[19] G. Lenz,et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[20] Steven J. M. Jones,et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. , 2013, Blood.
[21] Elaine S. Jaffe,et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.
[22] David Dunson,et al. Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[23] Yuh Min Chook,et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. , 2012, Blood.
[24] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[25] Steven J. M. Jones,et al. Recurrent targets of aberrant somatic hypermutation in lymphoma , 2012, Oncotarget.
[26] L. Staudt,et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.
[27] S. Knapp,et al. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma , 2012, British Journal of Cancer.
[28] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[29] Ryan D. Morin,et al. BCL2 mutations in diffuse large B-cell lymphoma , 2012, Leukemia.
[30] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[31] F. Jardin,et al. The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age , 2011, Haematologica.
[32] T. Molina,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial , 2011, The Lancet.
[33] J. Barthélémy,et al. Frequency of pain crises in sickle cell anemia and its relationship with the sympatho-vagal balance, blood viscosity and inflammation , 2011, Haematologica.
[34] Christian Steidl,et al. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. , 2011, Blood.
[35] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[36] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[37] A. Rosenwald,et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. , 2011, Blood.
[38] Tara L. Naylor,et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. , 2011, Cancer research.
[39] Steven J. M. Jones,et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.
[40] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[41] Gwendoline Dubois,et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. , 2009, Blood.
[42] W. Klapper,et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma , 2009, The Journal of experimental medicine.
[43] L. Staudt,et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.
[44] N. Shinton. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .
[45] S. Schurmans,et al. Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells , 2007, Proceedings of the National Academy of Sciences.
[46] T. Mattfeldt,et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation , 2006, Oncogene.
[47] H. Tagawa,et al. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8 , 2004, Oncogene.
[48] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[49] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] Ash A. Alizadeh,et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. , 2002, Blood.
[51] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[52] A. Kohlmann,et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients , 2014, Leukemia.
[53] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .